Skip to main content

Can heparin therapy reduce 28-day mortality in adult severe sepsis patients?

A study by Wang and colleagues [1] in a previous issue of Critical Care shows that heparin may reduce 28-day mortality in severe sepsis patients without causing an increased risk of bleeding. Therefore, the authors recommend the use of heparin for sepsis and severe sepsis. Although their result may significantly influence clinical practice, several confounding factors should be noticed.

In this study, eight studies performed analyses of mortality and seven studies performed analyses of bleeding events. From Additional file two, three non-randomized controlled trials (NRCTs) account for 88.42% of weight on mortality [2-4]; and from Figure three, two NRCTs account for 92.27% of weight on bleeding events [2,3]. In other words, the results of this meta-analysis are almost equivalent to those of the meta-analysis of these five NRCTs. Given the above analysis, the subgroup analyses in this study were unnecessary. However, the three studies were only placebo groups in three large multi-center randomized controlled trials [2-4]. Patients in these placebo groups were not randomly assigned to receive heparin or other therapy. In addition, it is possible that patients receiving heparin were less severe, because the Acute Physiology and Chronic Health Evaluation II score was not reported in these placebo groups. Moreover, as the initial times of heparin treatment were not defined clearly in the above three studies, we cannot rule out the possibility that patients who had died early would have no chance to receive heparin, whereas patients who had a longer survival would be more inclined to receive heparin. Finally, the dose of heparin in the three trials, and within each trial, was not controlled.

Abbreviations

NRCT:

Non-randomized controlled trial

References

  1. 1.

    Wang C, Chi C, Guo L, Wang X, Guo L, Sun J, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Crit Care. 2014;18:563.

    Article  Google Scholar 

  2. 2.

    Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869–78.

    CAS  Article  Google Scholar 

  3. 3.

    Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238–47.

    CAS  Article  Google Scholar 

  4. 4.

    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Mao Zhang.

Additional information

Competing interests

The authors declare that they have no competing interests.

See related research by Wang et al. http://ccforum.com/content/18/5/563

Li-bing Jiang and Yue-feng Ma contributed equally to this work.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jiang, Lb., Ma, Yf., Feng, X. et al. Can heparin therapy reduce 28-day mortality in adult severe sepsis patients?. Crit Care 19, 66 (2015). https://doi.org/10.1186/s13054-015-0768-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13054-015-0768-1

Keywords

  • Placebo
  • Heparin
  • Placebo Group
  • Subgroup Analysis
  • Emergency Medicine